ADXS Advaxis Inc.

-0.14  -37%
Previous Close 0.38
Open 0.28
Price To Book 0.5
Market Cap 16553744
Shares 69,495,149
Volume 3,962,103
Short Ratio
Av. Daily Volume 543,016

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Enrollment to be terminated - noted November 2, 2018.
Axalimogene filolisbac + durvalumab
Recurrent or refractory HPV-associated cervical cancer and head & neck cancer
Updated data due 1Q 2019.
ADXS-PSA and Keytruda - KEYNOTE-046
Castrate-resistant prostate cancer
Announced Phase 3 first patient dosed - February 6, 2017. Noted November 2, 2018 intention to continue trial.
Axalimogene filolisbac - AIM2CERV Trial
High-risk, locally advanced cervical cancer
Decided not to proceed to the expansion phase of the trial - noted in 10K December 21, 2017.
HER2-driven malignancies - cancer
Noted in 10-K December 21, 2017 that it will not initiate the Stage 2 portion of the trial in order to focus its resources on other clinical priorities.
Axalimogene filolisbac
Anal cancer (FAWCETT)
Phase 1 tolerability data due 1H 2019.
Non-small cell lung cancer (NSCLC)
Phase 1/2 trial to be initiated by the end of 2018 with initial data 1H 2019.
Non-small cell lung cancer (NSCLC)

Latest News

  1. Will Advaxis (ADXS) Report Negative Earnings Next Week? What You Should Know
  2. Could Advaxis, Inc.’s (NASDAQ:ADXS) Investor Composition Influence The Stock Price?
  3. Advaxis to Present at LD Micro Main Event
  4. Advaxis to Present Poster Entitled “Natural Killer (NK) Cells Orchestrate the Antitumor Activities of Listeria monocytogenes (Lm)-Based Immunotherapy” at Society for Immunotherapy of Cancer Annual Meeting
  5. Advaxis Provides Update on Clinical Pipeline
  6. Advaxis to Host Business Update Conference Call on November 2, 2018
  7. Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals — Discovering Underlying Factors of Influence
  8. Advaxis to Present at the Cantor Fitzgerald Global Healthcare Conference
  9. The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt
  10. Advaxis Inc (NASDAQ:ADXS): How Much Growth Is Left In Healthcare?
  11. Advaxis Announces Closing of Its Public Offering of Common Stock and Warrants
  12. The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet
  13. Advaxis: Fiscal 3Q Earnings Snapshot
  14. Advaxis Reports Fiscal 2018 Third Quarter Business Highlights and Financial Results
  15. Advaxis Announces Pricing of Its Public Offering of Common Stock and Warrants
  16. The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering
  17. Advaxis, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants
  18. Advaxis Licenses ADXS-HER2 to OS Therapies for Evaluation in the Treatment of Osteosarcoma
  19. Advaxis Announces FDA Allowance of IND Application for ADXS-HOT Drug Candidate for Non-Small Cell Lung Cancer

SEC Filings

  1. 8-K - Current report 181233556
  2. 8-K - Current report 181141644
  3. 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities 181128808
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 181070331
  5. 8-K - Current report 181065077
  6. 8-K - Current report 181063192
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 181063165
  8. 424B5 - Prospectus [Rule 424(b)(5)] 181062860
  9. 8-K - Current report 181059025
  10. 424B5 - Prospectus [Rule 424(b)(5)] 181058383